SCHEMBL3254149

SCHEMBL3254149

COC(=O)c1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)NC4CCCNC4)cc3c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 7/20 0.43
PARG Q86W56 1/20 0.43
KDR P35968 1/20 0.41
MAPT P10636 10/20 0.39
POLB P06746 8/20 0.39
TP53 P04637 7/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
BRAF P15056 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
IKBKB O14920 1/20 0.37
JAK2 O60674 1/20 0.37
ROCK2 O75116 1/20 0.37
JAK1 P23458 1/20 0.37
TYK2 P29597 1/20 0.37
JAK3 P52333 1/20 0.37
ROCK1 Q13464 1/20 0.37
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3251014 0.91 TDP1 (0.53) TDP1PARGMAPTPOLBTP53
SCHEMBL3242768 0.91 PARG (0.45) TDP1PARGKDRMAPTPOLB
SCHEMBL3252622 0.90 TDP1 (0.54) TDP1PARGMAPTPOLBTP53
SCHEMBL3255208 0.90 PARG (0.48) TDP1PARGKDRMAPTPOLB
SCHEMBL3249352 0.87 TDP1 (0.42) TDP1PARGKDRMAPTPOLB
SCHEMBL4159503 0.83 PARG (0.43) TDP1PARGKDRMAPTPOLB
SCHEMBL3247256 0.82 TDP1 (0.53) TDP1PARGMAPTPOLBTP53
SCHEMBL13928154 0.82 PARG (0.46) TDP1PARGKDRMAPTPOLB
SCHEMBL3250480 0.82 TDP1 (0.53) TDP1PARGMAPTPOLBTP53
SCHEMBL3254905 0.81 PARG (0.45) TDP1PARGKDRMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 TDP1 1098/4885PARG 3507/4885KDR 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.